Modulators of Caspase-6
AssigneesThe University of British Columbia, University of Hamburg
InventorsMehdi Mike Khankischpur, Olga Petina, Detief Gettken, Dabmar Ehmhoefer, Michael Hayden
Life of this patent
Estimating the term…
Abstract
Modulators of caspase-6 activity are provided for use in the treatment of neurodegenerative diseases.
Claims19
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with caspase-6 inhibitory activity and one or more pharmaceutically acceptable excipients, wherein the active agent has one of the following structures I or II, or a pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof:
- wherein Ra and Rb are independently linear or branched C1 to C6 alkyl, aryl, or alkenyl, C1 to C9 alkylaryl, C1 to C9 substituted alkylaryl, or C1 to C9 alkylheteroaryl;
- and
- wherein the phenyl group is substituted with 0, 1 or 2 halogens and further wherein the halogens are chloride, fluoride or bromide.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3a in FIG. 3A, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3b in FIG. 3B, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3c in FIG. 3C, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3d in FIG. 3D, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3e in FIG. 3E, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3f in FIG. 3F, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3g in FIG. 3G, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3h in FIG. 3H, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
A pharmaceutical composition for the treatment or amelioration of a neurological disease wherein the composition comprises a therapeutically effective amount of an active agent with the structure designated as PG-3 in FIG. 3, or pharmaceutically acceptable salt, stereoscopic isomer, derivative or prodrug thereof.
Dependencies are inferred from the claim text.